Aquestive Therapeutics resubmits NDA for Anaphylm
The company said it resubmitted its New Drug Application for Anaphylm after supportive human factors and pharmacokinetic study results.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.